Your browser doesn't support javascript.
loading
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Ries, Carola H; Cannarile, Michael A; Hoves, Sabine; Benz, Jörg; Wartha, Katharina; Runza, Valeria; Rey-Giraud, Flora; Pradel, Leon P; Feuerhake, Friedrich; Klaman, Irina; Jones, Tobin; Jucknischke, Ute; Scheiblich, Stefan; Kaluza, Klaus; Gorr, Ingo H; Walz, Antje; Abiraj, Keelara; Cassier, Philippe A; Sica, Antonio; Gomez-Roca, Carlos; de Visser, Karin E; Italiano, Antoine; Le Tourneau, Christophe; Delord, Jean-Pierre; Levitsky, Hyam; Blay, Jean-Yves; Rüttinger, Dominik.
Affiliation
  • Ries CH; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany. Electronic address: carola.ries@roche.com.
  • Cannarile MA; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Hoves S; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Benz J; Roche Innovation Center Basel, Small Molecule Research, Roche Pharmaceutical Research and Early Development, 4070 Basel, Switzerland.
  • Wartha K; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Runza V; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Rey-Giraud F; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Pradel LP; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Feuerhake F; Institute for Pathology, Hannover Medical School, 30625 Hannover, Germany.
  • Klaman I; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Jones T; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Jucknischke U; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Scheiblich S; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Kaluza K; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Gorr IH; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Walz A; Roche Innovation Center Basel, Pharmaceutical Sciences and Oncology Division, Roche Pharmaceutical Research and Early Development, 4070 Basel, Switzerland.
  • Abiraj K; Roche Innovation Center Basel, Pharmaceutical Sciences and Oncology Division, Roche Pharmaceutical Research and Early Development, 4070 Basel, Switzerland.
  • Cassier PA; Department of Medicine, Centre Léon Bérard, 69008 Lyon, France.
  • Sica A; Humanitas Clinical and Research Center, 20089 Milan, Italy; Department of Pharmaceutical Sciences, University of Piemonte, 28100 Novara, Italy.
  • Gomez-Roca C; Department of Medicine, Institut Claudius Regaud, 31000 Toulouse, France.
  • de Visser KE; Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Italiano A; Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France.
  • Le Tourneau C; Department of Medical Oncology, Institut Curie, 75248 Paris, France.
  • Delord JP; Department of Medicine, Institut Claudius Regaud, 31000 Toulouse, France.
  • Levitsky H; Roche Innovation Center Zurich, Oncology Division, Roche Pharmaceutical Research and Early Development, 8952 Zurich, Switzerland.
  • Blay JY; Department of Medicine, Centre Léon Bérard, 69008 Lyon, France.
  • Rüttinger D; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
Cancer Cell ; 25(6): 846-59, 2014 Jun 16.
Article in En | MEDLINE | ID: mdl-24898549
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptor, Macrophage Colony-Stimulating Factor / Colonic Neoplasms / Macrophages / Antibodies, Monoclonal Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Female / Humans / Male Language: En Year: 2014 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptor, Macrophage Colony-Stimulating Factor / Colonic Neoplasms / Macrophages / Antibodies, Monoclonal Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Female / Humans / Male Language: En Year: 2014 Type: Article